Polymorphisms in adipokine-related genes to predict treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy.

被引：0
|
作者：
Miyamoto, Yuji
Stintzing, Sebastian
Zhang, Wu
Cao, Shu
Ning, Yan
Okazaki, Satoshi
Berger, Martin D.
Suenaga, Mitsukuni
Schirripa, Marta
Soni, Shivani
Matsusaka, Satoshi
Yang, Dongyun
Gopez, Roel
Hanna, Diana L.
Barzi, Afsaneh
Baba, Hideo
Heinemann, Volker
Lenz, Heinz-Josef
机构：
[1] USC Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA
[2] Ludwig Maximilian Univ Munich, Munich, Germany
[3] USC Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA USA
[4] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto, Japan
[5] Ludwig Maximilian Univ Munich, Comprehens Canc Ctr, Munich, Germany
[6] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive value of VEGF gene polymorphisms in metastatic colorectal cancer patients treated with a bevacizumab-based chemotherapy.
    Ulivi, Paola
    Marisi, Giorgia
    Scarpi, Emanuela
    Passardi, Alessandro
    Ragazzini, Angela
    Frassineti, Giovanni Luca
    Zoli, Wainer
    Valgiusti, Martina
    Nanni, Oriana
    Calistri, Daniele
    Casacci, Fabio
    Amadori, Dino
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy.
    Miyamoto, Yuji
    Loupakis, Fotios
    Zhang, Wu
    Cao, Shu
    Okazaki, Satoshi
    Berger, Martin D.
    Suenaga, Mitsukuni
    Schirripa, Marta
    Soni, Shivani
    Matsusaka, Satoshi
    Ning, Yan
    Yang, Dongyun
    Gopez, Roel
    Melendez, Elizabeth
    Hanna, Diana L.
    Barzi, Afsaneh
    Baba, Hideo
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.
    Tokunaga, Ryuma
    Cao, Shu
    Puccini, Alberto
    Naseem, Madiha
    Battaglin, Francesca
    Barzi, Afsaneh
    Millsteinand, Joshua
    Soni, Shivani
    Berger, Martin D.
    McSkane, Michelle
    Zhang, Wu
    Loupakis, Fotios
    Cremolini, Chiara
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.
    Miyamoto, Yuji
    Stintzing, Sebastian
    Heinemann, Volker
    Zhang, Wu
    Cao, Shu
    Okazaki, Satoshi
    Berger, Martin D.
    Suenaga, Mitsukuni
    Schirripa, Marta
    Soni, Shivani
    Matsusaka, Satoshi
    Ning, Yan
    Yang, Dongyun
    Gopez, Roel
    Melendez, Elizabeth
    Hanna, Diana L.
    Barzi, Afsaneh
    Baba, Hideo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Defective mismatch repair (dMMR) status as a predictive biomarker in Chinese patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy.
    Ling, Jiayu
    Chen, Dianke
    Zhang, Jianwei
    Zhong, Lixing
    Cai, Yue
    Deng, Yanhong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
    Satoshi Matsusaka
    Mitsukuni Suenaga
    Yuji Mishima
    Koichi Takagi
    Yasuhito Terui
    Nobuyuki Mizunuma
    Kiyohiko Hatake
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 68 : 763 - 768
  • [7] Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
    Matsusaka, Satoshi
    Suenaga, Mitsukuni
    Mishima, Yuji
    Takagi, Koichi
    Terui, Yasuhito
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 763 - 768
  • [8] IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
    Di Salvatore, Mariantonietta
    Pietrantonio, Filippo
    Orlandi, Armando
    Del Re, Marzia
    Berenato, Rosa
    Rossi, Ernesto
    Caporale, Marta
    Guarino, Donatella
    Martinetti, Antonia
    Basso, Michele
    Mennitto, Roberta
    Santonocito, Concetta
    Mennitto, Alessia
    Schinzari, Giovanni
    Bossi, Ilaria
    Capoluongo, Ettore
    Danesi, Romano
    de Braud, Filippo
    Barone, Carlo
    [J]. ONCOTARGET, 2017, 8 (10) : 16887 - 16898
  • [9] VEGF and eNOS gene polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in patients with metastatic colorectal cancer
    Ulivi, P.
    Passardi, A.
    Marisi, G.
    Casacci, F.
    Scarpi, E.
    Valgiusti, M.
    Calistri, D.
    Del Re, M.
    Frassineti, G. L.
    Amadori, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S563 - S563
  • [10] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
12345